EUVIMEDEUVIMED entdecken
Crossref

Advances in the Efficacy of Category II Improved New Drugs for Bipolar Disorder—Evidence from Randomized Controlled Trials and Real-World Studies

歆睿 张

International Journal of Psychiatry and Neurology · 2026 · 15 (04) · 160-168

DOI: 10.12677/ijpn.2026.154018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Psychiatry and Neurology, 2026. Verfasst von 歆睿 张. Die Arbeit nennt 53 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

张, 歆. (2026). Advances in the Efficacy of Category II Improved New Drugs for Bipolar Disorder—Evidence from Randomized Controlled Trials and Real-World Studies. International Journal of Psychiatry and Neurology, 15(04), 160-168. https://doi.org/10.12677/ijpn.2026.154018

Vancouver

张 歆. Advances in the Efficacy of Category II Improved New Drugs for Bipolar Disorder—Evidence from Randomized Controlled Trials and Real-World Studies. International Journal of Psychiatry and Neurology. 2026;15(04):160-168. doi:10.12677/ijpn.2026.154018

BibTeX
@article{2026,
  author = {张, 歆睿},
  title = {Advances in the Efficacy of Category II Improved New Drugs for Bipolar Disorder—Evidence from Randomized Controlled Trials and Real-World Studies},
  journal = {International Journal of Psychiatry and Neurology},
  year = {2026},
  volume = {15},
  number = {04},
  pages = {160--168},
  doi = {10.12677/ijpn.2026.154018}
}
Kostenlos starten →